Tirzepatide
The first dual GLP-1/GIP receptor agonist, achieving unprecedented weight loss results of up to 22.5% body weight reduction. Marketed as Mounjaro and Zepbound.
24 min read · Last updated March 2026 · 45+ research citations
FDA-Approved Prescription Medication: Tirzepatide is approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It requires a prescription and medical supervision.
Key Takeaways
Overview
What is Tirzepatide?
Tirzepatide is a synthetic peptide that functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by Eli Lilly and Company, it represents a first-in-class medication that simultaneously activates two key incretin hormone receptors involved in glucose metabolism and appetite regulation.
Development Timeline
Global Regulatory Approvals
Brand Names
Mounjaro vs Zepbound
Mounjaro
FDA approved May 2022 for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise.
Zepbound
FDA approved November 2023 for chronic weight management in adults with obesity or overweight with comorbidities.
Chemistry
Molecular Structure & Pharmacology
Amino Acid Sequence
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
Aib Substitutions
Aminoisobutyric acid at positions 2 and 13 confers resistance to DPP-4 degradation, dramatically extending half-life.
C20 Fatty Diacid
Fatty acid chain at lysine-20 enables albumin binding, extending half-life to ~5 days for once-weekly dosing.
C-Terminal Amidation
The amidated C-terminus enhances receptor binding affinity and metabolic stability.
Mechanism
How Tirzepatide Works
Dual activation of GIP and GLP-1 receptors produces synergistic effects on metabolism
GLP-1 Receptor Effects
Glucose-dependent insulin secretion, glucagon suppression
Appetite reduction through hypothalamic signaling
Slowed gastric emptying, reduced glucose excursions
GIP Receptor Effects
Enhanced insulin secretion, synergistic with GLP-1
Improved insulin sensitivity, reduced ectopic fat
May support bone formation and mineral density
Synergistic Benefits of Dual Agonism
Enhanced Insulin
Dual incretin effect produces more robust glucose-dependent release
Superior Appetite Control
GIP adds central satiety signals beyond GLP-1 alone
Better Body Composition
Preferential fat loss while preserving lean muscle mass
Metabolic Flexibility
Improved switching between carbohydrate and fat metabolism
Evidence
Clinical Research Evidence
Two comprehensive clinical trial programs: SURPASS (diabetes) and SURMOUNT (obesity)
SURPASS Trials (Type 2 Diabetes)
SURPASS-2 vs Semaglutide
Head-to-Head| Outcome | Semaglutide 1mg | TZP 15mg |
|---|---|---|
| HbA1c Change | -1.86% | -2.30% |
| Weight Loss | -5.7 kg | -11.2 kg |
| HbA1c <5.7% | 20% | 46% |
SURPASS-1 Monotherapy
40 weeks| Outcome | Placebo | TZP 15mg |
|---|---|---|
| HbA1c Change | -0.1% | -2.07% |
| Weight Loss | -1.0 kg | -9.5 kg |
| HbA1c <7% | 23% | 88% |
SURMOUNT Trials (Obesity/Overweight)
SURMOUNT-1 (Landmark Obesity Trial)
72 weeks • n=2,539| Outcome | Placebo | TZP 5mg | TZP 10mg | TZP 15mg |
|---|---|---|---|---|
| Weight Loss | -3.1% | -15.0% | -19.5% | -20.9% |
| ≥10% Weight Loss | 14% | 69% | 79% | 84% |
| ≥20% Weight Loss | 3% | 32% | 50% | 57% |
The 20.9% average weight loss at the highest dose represents the most significant weight reduction ever achieved by any approved medication in clinical trials.
Efficacy
Weight Loss Results
Body Composition Effects
Metabolic Improvements
Comparison
Tirzepatide vs Semaglutide
| Aspect | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor Targets | GLP-1 only | GLP-1 + GIP (dual) |
| Max Weight Loss (trials) | ~15% | ~21% |
| HbA1c Reduction | -1.86% | -2.30% |
| Half-Life | ~7 days | ~5 days |
| Oral Form Available | Yes (Rybelsus) | No |
| CV Outcomes Data | Completed (SELECT) | Ongoing |
| Nausea Rate | 44% | 25-33% |
Based on SURPASS-2 head-to-head trial and cross-trial comparisons. Individual results may vary.
Protocols
Dosage Information
FDA-Approved Dose Escalation Schedule
| Week | Dose | Purpose |
|---|---|---|
| Weeks 1-4 | 2.5 mg | Starting dose (tolerability) |
| Weeks 5-8 | 5 mg | Initial therapeutic dose |
| Weeks 9-12 | 7.5 mg | Escalation (if tolerated) |
| Weeks 13-16 | 10 mg | Mid-range maintenance |
| Weeks 17-20 | 12.5 mg | Further escalation |
| Week 21+ | 15 mg | Maximum dose |
Administration
- • Subcutaneous injection only
- • Sites: Abdomen, thigh, or upper arm
- • Same day each week, time flexible
- • With or without food
- • Refrigerate; room temp up to 21 days
Missed Dose
If missed, take within 4 days of scheduled day. If more than 4 days passed, skip the missed dose and resume on next scheduled day. Never take two doses at once.
Safety
Side Effects & Safety
Common Side Effects
Boxed Warning
Thyroid C-Cell Tumors: In rodents, tirzepatide causes thyroid C-cell tumors. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
Contraindications
Who Should NOT Use Tirzepatide
Absolute Contraindications
Use with Caution
FAQ
Frequently Asked Questions
References
- Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.
- Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20 Suppl 1:5-21.
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Mol Metab. 2018;18:3-14.
- U.S. Food and Drug Administration. FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes. FDA News Release. May 13, 2022.
- Mounjaro (tirzepatide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2022.
- Zepbound (tirzepatide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2023.
- Rosenstock J, et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
- Garvey WT, et al. Tirzepatide for obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). Lancet. 2024;403(10428):e11.
- Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
- Sattar N, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591-598.
Disclaimer: This page is for educational and informational purposes only. Tirzepatide is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Always consult your healthcare provider before starting, stopping, or changing any medication.
Last updated: March 2026 · Reviewed by: Scientific Aminos Editorial Board
Order Tirzepatide Wholesale
US-manufactured, HPLC verified. Available for distributors, telehealth providers, clinics, and research institutions.